What are the the biggest opportunities for monoclonal antibodies at a global and Asian level? What are some of major challenges in the antibody development in Asia? What are the key strategies in overcoming these challenges?
We had an exclusive interview with Ming-Qiang Zhang, Vice President & Head, Research & Development China, Amgen Inc to address the opportunities and challenges faced by the Asian antibody industry and the strategies employed to overcome key pressing issues.
> Download the interview
Ming-Qiang Zhang will be speaking at Asia Antibody Congress 2013 19 June 2013, 910 – Panel: Achieving success in Asian regulatory compliance for therapeutic antibodies and on 19 June 2013, 1120- Antibody R&D in China: Challenges and Opportunities.
See another interview: Interview with Francisco Leon – Insights on Monoclonal Antibodies (mAbs)